Login
$BFRI
$0.59 +$0.02 (3.79%) After hours

$BFRI 8-K SEC Filings

Filed On Filing
13 Nov 2026 8-K: Results of Operations and Financial Condition

WOBURN, Mass., November 13, 2026 — Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today re...

14 Sep 2026 8-K: Other Events

Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera’s photodynamic therapy plat...

13 Aug 2026 8-K: Results of Operations and Financial Condition

WOBURN, Mass., August 13, 2026 — Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today repo...

17 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 11, 2026, Biofrontera Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). Proxies for the Annual Meeting were solicited pursuant to Regulation 14A under the Securities Exchange Act of 1934, and th...

14 May 2026 8-K: Results of Operations and Financial Condition

Woburn, MA (May 14, 2026) (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ: BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported ...

19 Mar 2026 8-K: Results of Operations and Financial Condition

Woburn, MA (March 19, 2026) (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported...

09 Mar 2026 8-K: Regulation FD Disclosure

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

26 Feb 2026 8-K: Other Events

U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable

09 Feb 2026 8-K: Regulation FD Disclosure

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint

13 Jan 2026 8-K: Results of Operations and Financial Condition

Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth

07 Jan 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

13 Nov 2025 8-K: Results of Operations and Financial Condition

November 13, 2025 (GLOBE NEWSWIRE) Woburn, MA — Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reporte...

10 Nov 2025 8-K: Other Events

As described further below, on each of November 4, 2025 and November 6, 2025, Biofrontera Inc. (the “Company”) received a notice (the “November 4 Notice” and the “November 6 Notice,” respectively) from the Listing Qualifications staff of...

07 Nov 2025 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +1 more

Form of Bill of Sale and Assignment and Assumption Agreement

24 Oct 2025 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more

THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made as of October 20, 2025, by and between Biofrontera AG, a German corporation (“AG”), Biofrontera Pharma GmbH, a German private limited liability company (“Pharma”), Biofrontera Bios...

23 Oct 2025 8-K: Regulation FD Disclosure

Biofrontera Inc. acquires full U.S. rights to Ameluz® and RhodoLED®, including New Drug Application and associated patents, from former parent Biofrontera AG.

19 Sep 2025 8-K: Submission of Matters to a Vote of Security Holders

On September 16, 2025, Biofrontera Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). Proxies for the Special Meeting were solicited pursuant to Regulation 14A under the Securities Exchange Act of 1934, ...

13 Aug 2025 8-K: Results of Operations and Financial Condition

Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financi...

11 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

This Employment Agreement (the “Agreement”) is made as of July 18, 2025 (the “Effective Date”), by and between Biofrontera, Inc, a Delaware corporation (the “Company”) having its principal office at 120 Presidential Way, Suite 330, Wobur...

01 Jul 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This Securities Purchase Agreement (this “Agreement”) is dated as of June 27, 2025, by and among Biofrontera Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its s...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support